Serotonin (5HT) and its antagonists: involvement in the cardiovascular system
- PMID: 6098391
- DOI: 10.1111/j.1440-1681.1984.tb00852.x
Serotonin (5HT) and its antagonists: involvement in the cardiovascular system
Abstract
The cardiovascular actions of serotonin and its antagonists are reviewed with a view to clarifying whether serotonin has a role in blood pressure control through actions on the peripheral vasculature. Serotonin has complex actions in the heart and vasculature but none of these actions is completely understood. There is no doubt, however, that serotonin has extensive interactions with the sympathetic nervous system. The nature of the serotonin receptor is also discussed. There is extensive evidence that more than one type of serotonin receptor exists. Biochemical studies in brain homogenates have delineated two sub-populations of serotonin receptors, named 5HT1 and 5HT2. It is not clear whether the same receptor types exist in the vasculature but various actions of serotonin on the vasculature have tentatively been ascribed to actions on 5HT1- and 5HT2-type receptors. It is clear that there is some functional overlap between serotonin-receptors and alpha-adrenoceptors. The mechanism by which this overlap could occur is unknown although we suggest it may result from a physical overlap of serotonin receptors and alpha-adrenoceptors. Compounds which antagonize serotonin have provided the means for investigating serotonin receptors but have not clarified the role of serotonin in blood pressure control; certainly they have comparatively little effect on blood pressure and this may simply reflect the lack of free circulating serotonin. In animal studies the new serotonin antagonist ketanserin appears to lower blood pressure via alpha-adrenoceptor blockade.
Similar articles
-
Hypotensive activity of serotonin antagonists; correlation with alpha 1-adrenoceptor and serotonin receptor blockade.Life Sci. 1983 Mar 28;32(13):1499-505. doi: 10.1016/0024-3205(83)90916-5. Life Sci. 1983. PMID: 6300582
-
Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats.Hypertension. 1983 Sep-Oct;5(5):676-81. doi: 10.1161/01.hyp.5.5.676. Hypertension. 1983. PMID: 6311738
-
Effects of bunitrolol on adrenergic and serotonergic receptors.Jpn J Pharmacol. 1987 Nov;45(3):349-56. doi: 10.1254/jjp.45.349. Jpn J Pharmacol. 1987. PMID: 2893855
-
Pharmacology of potent and selective S2-serotonergic antagonists.J Cardiovasc Pharmacol. 1985;7 Suppl 7:S2-11. doi: 10.1097/00005344-198500077-00002. J Cardiovasc Pharmacol. 1985. PMID: 2412048 Review.
-
Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.Drugs. 1990;40 Suppl 4:1-8; discussion 28-30. doi: 10.2165/00003495-199000404-00003. Drugs. 1990. PMID: 1982649 Review.
Cited by
-
An examination of 5-hydroxytryptamine receptors in human saphenous vein.Br J Pharmacol. 1986 Sep;89(1):77-81. doi: 10.1111/j.1476-5381.1986.tb11122.x. Br J Pharmacol. 1986. PMID: 3801780 Free PMC article.
-
5-HTR3 and 5-HTR4 located on the mitochondrial membrane and functionally regulated mitochondrial functions.Sci Rep. 2016 Nov 22;6:37336. doi: 10.1038/srep37336. Sci Rep. 2016. PMID: 27874067 Free PMC article.
-
Serotonin and blood pressure regulation.Pharmacol Rev. 2012 Apr;64(2):359-88. doi: 10.1124/pr.111.004697. Epub 2012 Mar 8. Pharmacol Rev. 2012. PMID: 22407614 Free PMC article. Review.
-
Investigations of cardiovascular 5-hydroxytryptamine receptor subtypes in the rat.Naunyn Schmiedebergs Arch Pharmacol. 1988 Jan;337(1):1-8. doi: 10.1007/BF00169468. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3368008
-
Potential Clinical Value of 5-Hydroxytryptamine Receptor 3C as a Prognostic Biomarker for Lung Cancer.J Oncol. 2021 Nov 15;2021:1901191. doi: 10.1155/2021/1901191. eCollection 2021. J Oncol. 2021. PMID: 34868311 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
